JP Morgan Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $32
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan analyst Anupam Rama initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $32.
JP Morgan analyst Anupam Rama initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $32.